Context Therapeutics highlights 2023 priorities: CTIM-76 candidate, ONA-XR data updates, cash runway into Q1 2024

Context Therapeutics Inc.

CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody candidate; IND filing expected Q1 2024.
ONA-XR Phase 2 endometrial cancer (OATH) shows 77% 4-month PFS rate; additional data expected mid-2023.
ONA-XR Phase 2 breast cancer (SMILE) shows 44% 4-month PFS rate; additional data expected Q4 2023.
ELONA Phase 1b/2 breast cancer trial with Menarini's elacestrant opened and enrolled first patient.
Cash and equivalents $39.4M as of Sep 30, 2022; expected to fund operations into Q1 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.